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OBJECTIVES The study aimed to evaluate the role of alpha-adrenergic mechanisms during dynamic
exercise in both normal and stenotic coronary arteries.
BACKGROUND Paradoxical vasoconstriction of stenotic coronary arteries has been reported during dynamic
exercise and may be due to several factors such as alpha-adrenergic drive, a decreased release
of nitric oxide, platelet aggregation with release of serotonin, or a passive collapse of the vessel
wall.
METHODS Twenty-six patients were studied at rest, during two levels of supine bicycle exercise and after
1.6 mg sublingual nitroglycerin. The alpha-blocker phentolamine was given to 16 patients
before exercise, five of whom had also taken a beta-adrenergic-blocker the same morning.
Ten patients served as controls. The cross-sectional areas of a normal and a stenotic coronary
vessel were determined by biplane quantitative coronary arteriography.
RESULTS In the normal vessel segments, coronary cross-sectional area did not change after phentol-
amine injection, but increased in all patient groups similarly during exercise. Although
coronary vasoconstriction existed in stenotic vessel segments in control patients,
phentolamine-treated patients showed exercise-induced vasodilation without difference in
patients with and without chronic beta-blockade.
CONCLUSIONS Exercise-induced vasoconstriction of stenotic coronary arteries is prevented by intracoronary
administration of phentolamine. There was no difference in coronary vasomotion between
patients receiving phentolamine alone and patients receiving phentolamine in addition to a
beta-blocker. This finding suggests that exercise-induced vasoconstriction is mediated not
only by endothelial dysfunction but also by alpha-adrenergic mechanisms. (J Am Coll
Cardiol 1999;33:1499–505) © 1999 by the American College of Cardiology
Coronary vasomotor tone plays an important role in the
pathophysiology of angina pectoris. An increase in vasomo-
tor tone of stenotic arteries may result in a decrease in
coronary blood flow and, thus, may precipitate myocardial
ischemia. A reduction in exercise-induced angina pectoris
and an increase in physical working capacity have been
reported in patients with stable angina pectoris after intra-
coronary administration of phentolamine (1,2) or in-
doramine, a selective alpha1-adrenoceptor antagonist (3).
Stenotic coronary arteries have shown paradoxical vasocon-
striction during isometric (4) but also dynamic exercise (5).
This exercise-induced narrowing of the stenotic arteries has
been prevented by intracoronary administration of nitro-
glycerin (4) or diltiazem in doses that did not induce
systemic vascular effects (6).
The exact mechanism that is responsible for the reported
stenosis vasoconstriction is not clear but may involve several
factors such as an enhanced sympathetic stimulation during
exercise, endothelial dysfunction with reduced nitric oxide
(NO) release or production, increased platelet aggregation
with release of serotonin and thromboxane A2, or a passive
collapse of the stenotic vessel segment within the stenosis due
to the increase in flow velocity during exercise (Venturi effect).
Because changes in coronary vasomotor tone underlie
neurogenic mechanisms, particular interest has focused on
the link between myocardial ischemia and alpha-adrenergic
tone during exercise. Thus, the purpose of the present study
was to assess the influence of alpha-adrenergic mechanisms
on coronary vasomotion in normal and stenotic coronary
arteries during dynamic exercise.
METHODS
Study population. Twenty-six patients (mean age 54 6 8
years) with coronary artery disease and stable angina pecto-
ris were included in the present analysis. Biplane coronary
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angiography was performed at rest, during supine bicycle
exercise and after sublingual nitroglycerin. Patients who
fulfilled the following baseline criteria were included in the
study: 1) a history of stable, effort-related angina pectoris
and 2) coronary artery stenosis clearly visible on angiography
for quantitative evaluation. The first 10 of the studied
patients did not receive any premedication prior to exercise
and they served as controls (C). The remaining 16 patients
obtained before exercise 2 mg intracoronary phentolamine,
a nonselective alpha-blocker (P). Although 11 patients of
this group did not have any vasoactive substances for at least
24 h before the study (Pa), five patients who were on
chronic cardioselective beta-blockade (metoprolol or ateno-
lol) had been instructed to take this medication also on the
morning of the study (Pa 1 b).
Functional classification according to the New York
Heart Association was 1.9 6 0.6 in controls and 1.8 6 0.9
in the phentolamine-treated patients (not significant [NS]).
In the phentolamine-treated group, 4/11 patients had one-
vessel disease, 4/11 patients had two-vessel disease, and
3/11 patients had three-vessel disease. Two patients who
were pretreated with a beta-adrenergic-blocker and then
received phentolamine during the study protocol were
suffering from one-vessel disease, one had a two-vessel
disease and two had a three-vessel disease. Of the control
patients one-vessel disease was present in 4/10 patients,
two-vessel disease was found in 3/10 patients, and three-
vessel disease was present in 3/10 patients. Maximal stenosis
severity for patients with phentolamine was ,70% in three,
70% to 90% in four and .90% in three cases. For patients
with alpha- and beta-blockade stenosis, severity amounted
to 70% to 90% in 4 patients and ,70% in 1 patient. One
control patient had a ,70% stenosis, seven had 70% to 90%
stenoses, and 2 had .90% stenoses. Left ventricular ejection
fraction averaged 61 6 8% in controls and 64 6 6% in
phentolamine-treated patients (NS).
Cardiac catheterization. The study protocol was approved
by the local ethics committee, and written informed consent
was obtained from all patients. Vasoactive substances were
withheld for at least 24 h before catheterization except in
the five patients who received chronically a cardioselective
beta-blocker. The catheter was inserted through the right
femoral artery and was kept in place during supine bicycle
exercise. Biplane left coronary angiography was performed
at the end of the diagnostic coronary angiography. For the
purpose of the present study protocol, the left coronary
artery was selected to have a normal and a stenotic vessel
segment for quantitative analysis. The study drug was,
therefore, infused over the guiding catheter into the left
coronary artery. Eight milliliters of a nonionic contrast
material (Jopamiro 370R) was injected into the left coronary
artery at a flow rate of 4 ml/s using an electrogram-triggered
power-injector.
First, biplane coronary angiography was carried out at rest
with the patients’ legs elevated and attached to the bicycle
ergometer. Angiography was performed on a Bicor Siemens
system (Siemens Albis AG, Zurich) using cinefilm at a rate
of 25 frames/s. Further biplane coronary angiograms were
performed after administration of 2 mg intracoronary phen-
tolamine (Infusion time: 5 min; 0.4 mg/min). Two levels of
supine bicycle exercise were performed for 2 min in each
patient. Biplane coronary angiography was repeated imme-
diately after each exercise level while the patient was asked
to hold his breath. Finally, coronary angiography was
carried out 5 min following administration of 1.6 mg
sublingual nitroglycerin. Aortic and pulmonary artery pres-
sures were recorded continuously during exercise and were
measured for subsequent analysis immediately before each
angiogram. No adverse event occurred during the study, and
there were no complications with regard to this study
protocol.
Quantitative coronary angiography. Quantitative angio-
graphy was carried out with a semiautomatic computer
system (7–9). The system is based on a 35-mm film
projector (Tagarno 35 CX, Horsens, Denmark), a slow scan
CCD-camera for image digitation and a computer work-
station (Apollo DN 3000, Wangen, Switzerland) for image
storing and processing. Contour detection was carried out
with the use of a geometric-densitometric edge detection
algorithm (8,10,11). The method for quantitative evaluation
of coronary angiography has been described in detail else-
where (5,7,10,11).
Both a normal and a stenotic vessel segment were chosen
for quantitative analysis. In each patient at least one stenotic
vessel was selected for analysis on the basis of clear visual-
ization without overlapping vessels. The normal vessel
segment was selected from a disease-free vessel when
possible, otherwise an uninvolved prestenotic vessel segment
was chosen at least four catheter-widths from the center of
the stenosis, which was not used for quantiative evaluation
(Fig. 1).
Statistical analysis. Statistical comparisons of hemody-
namic and angiographic data among as well as between the
patients were carried out by a two-way analysis of variance
(ANOVA) for repeated measurements. If this test was
significant, the Scheffe´ procedure was applied to determine
the intra- and intergroup statistical differences. A p-value of
less than 0.05 was considered to indicate statistical signifi-
Abbreviations and Acronyms
ANOVA5 analysis of variance
C 5 controls
CSA 5 cross-sectional area
NS 5 not significant
P 5 patients receiving intracoronary phentolamine
P(a) 5 patients receiving only phentolamine
P(a 1 b) 5 patients on chronic beta-blockade receiving
phentolamine
SD 5 standard deviation
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cance. Data in all tables and figures are reported as mean 6
1 standard deviation (SD).
RESULTS
Clinical findings. Patients in the two groups did not differ
with respect to age, gender and functional classification
according to the New York Heart Association or baseline
hemodynamic values. Left ventricular ejection fraction was
slightly lower in patients on chronic beta-blockade (P(a 1 b))
when compared with those without beta-blockers. Baseline
hemodynamic data are summarized in Table 1. Physical
working capacity was similar in the two groups (C: 109 6
25 W, P: 100 6 21 W; NS). Angina pectoris during supine
bicycle exercise was present in four out of ten patients (40%)
in C and 5 out of 16 patients in P (31%). Heart rate did not
change after intracoronary phentolamine injection and in-
creased to a similar extent in the two groups during exercise.
Patients on chronic beta-blockade had a significantly lower
rate-pressure product than did controls or P(a) (14.3 6 2.7
vs. 20.8 6 3.8 and 18.7 6 3.8 mm Hg/minz103, respec-
tively; p , 0.05) (Fig. 2). Mean aortic and mean pulmonary
artery pressures remained unchanged after intracoronary
phentolamine administration but increased similarly in all
groups during exercise (Table 2).
Coronary cross-sectional area (CSA). Percent changes in
coronary CSA of the normal and stenotic vessels are
illustrated in Figure 3. The size of the normal vessel
remained unchanged after administration of intracoronary
phentolamine (105 6 7.8%), but increased during exercise
(C: 113 6 11%; P: 117 6 18%; NS) as well as after
administration of sublingual nitroglycerin (C: 123 6 15%;
P: 132 6 21%; NS). There was no difference in patients
with or without chronic beta-blockade after phentolamine
administration (P(a): 104 6 11%, P(a 1 b): 107 6 10%; NS).
During exercise, CSA increased in both groups (P(a): 117 6
11% and P(a 1 b): 118 6 28%; NS) and the CSA was
maximally dilated after sublingual nitroglycerin (P(a): 136 6
20% and P(a 1 b): 125 6 22%; NS).
Coronary CSA of the stenotic vessel remained unchanged
after intracoronary administration of phentolamine (104 6
8%). While phentolamine-treated patients showed exercise-
induced vasodilation (113 6 8%), there was coronary
vasoconstriction during exercise in controls (85 6 23%; p ,
0.001). Vasodilation of the stenotic vessel segment was
similar after sublingual nitroglycerin in both groups (C:
Figure 1. Quantitative coronary angiography of the left anterior
descending coronary artery in a patient with moderate lesion in
Aldrigde projection. Automatic evaluation of the stenotic segment
was performed by computer analysis. The proximal and distal
reference segments are marked with two lines. The minimal
luminal diameter was 2.6 mm at Rest, 2.7 mm after intracoronary
phentolamine (Reg), 2.6 mm during the first (Ex 1) and 2.6 mm
during the second (Ex 2) exercise level, and amounted to 3.0 mm
after sublingual nitroglycerin (NTG).
Table 1. Hemodynamic Data
LVEDP
(mm Hg)
MAP
(mm Hg)
MPAP
(mm Hg)
CI
(l/min/m2)
EF
(%)
Controls 14 6 6 101 6 11 19 6 6 2.8 6 1.0 61 6 8
a-Blocker 10 6 3 102 6 16 18 6 6 2.8 6 0.6 66 6 4
a 1 b-Blocker 11 6 2 92 6 9 14 6 5 2.9 6 1.0 58 6 6
C vs. a NS NS NS NS NS
C vs. a 1 b NS NS NS NS NS
a vs. a 1 b NS NS NS NS p , 0.05
LVEDP, left ventricular end-diastolic pressure; MAP, mean aortic pressure; MPAP, mean pulmonary artery pressure; CI,
cardiac index; EDV, end-diastolic volume; a, patients receiving phentolamine; a 1 b, patients on chronic beta-blockade
receiving phentolamine before supine bicycle exercise testing; C, controls.
Figure 2. Rate-pressure product (RPP) and mean pulmonary
artery pressure (mPAP) at rest (R), after intracoronary adminis-
tration of phentolamine (Drug), during two levels of supine bicycle
exercise (Ex1; Ex2), and after sublingual nitroglycerin administra-
tion (NTG). Note the significant rise of both parameters during
exercise. However, patients on chronic beta-blockade reached a
lower rate-pressure product than did the two other groups. Open
circles 5 alpha-blockers; solid circles 5 alpha- plus beta-
blockers; solid triangles 5 control group. NTG 5 nitroglycerin.
*p , 0.05 versus alpha- plus beta-blockers.
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116 6 19%; P: 119 6 14%; NS), but was less in the stenotic
than in the normal vessel segment (p , 0.05). There was no
difference in the behavior of the stenotic vessel segments in
patients with and those without chronic beta-blockade after
phentolamine administration (P(a): 102 6 7%, P(a 1 b):
109 6 5%) as well as during exercise (P(a): 112 6 8% and
P(a 1 b): 113 6 10%) and after nitroglycerin administration
(P(a): 119 6 15% and P(a 1 b): 119 6 10%) (all NS). For
absolute values, see Table 3. The main findings are also
illustrated in Figure 3.
DISCUSSION
Alpha-adrenoceptor activation causes a number of different
reactions in the intact heart including the activation of
sympathetic nerve endings with feedback inhibition of
norepinephrine release (12,13); a stimulation of cardio-
myocytes with a positive inotropic effect and prolongation
of contraction by increasing intracellular calcium-
concentration (14,15); increased platelet aggregation (16)
and an enhanced release of endothelium-derived growth
factors (17). Data on the contribution of vascular alpha1-
and alpha2-adrenoceptors to the constriction of the large
epicardial conductance and small resistance vessels as well as
collateral vessels are controversial (18).
Alpha-adrenergic vasomotion in normal coronary arter-
ies. Alpha-receptor dependent vasomotion of the normal
coronary arteries is of minor physiologic importance, be-
cause resistance of the epicardial coronary arteries contrib-
utes only 5% to total coronary resistance (19). In the
presence of beta-adrenergic blockade, the increase in epi-
Table 2. Exercise Data
Ex
(Watt)
HR
(beats/min)
MAP
(mm Hg)
MPAP
(mm Hg)
RPP
(103 mm Hg/min)
B Ex B Ex B Ex B Ex
Controls 109 6 25 66 6 15 112 6 29 101 6 10 116 6 23 19 6 6 40 6 10 9.9 6 2 20.8 6 3.8
a-Blocker 95 6 21 67 6 13 111 6 15 102 6 16 120 6 13 18 6 6 35 6 13 9.8 6 3 18.7 6 2.5
a 1 b-Blocker 112 6 18 59 6 12 102 6 10 92 6 9 108 6 13 14 6 4 35 6 3 7.0 6 2 14.3 6 2.7
C vs. a NS NS NS NS NS NS NS NS NS
C vs. a 1 b NS NS NS NS NS NS NS NS NS
a vs. a 1 b NS NS NS NS NS NS NS p , 0.05 p , 0.05
Ex 5 exercise; B 5 baseline; HR 5 heart rate; MAP 5 mean aortic pressure; MPAP 5 mean pulmonary artery pressure; RPP 5 rate pressure product; a 5 patients receiving
phentolamine; a 1 b 5 patients on chronic beta-blockade receiving phentolamine before supine bicycle exercise testing; C 5 controls.
Figure 3. Responses of normal and stenotic coronary arteries to dynamic exercise after intracoronary phentolamine administration in
patients without (a; upper panel) and with chronic beta-blockade (a 1 b; lower panel). For comparison purposes, data are shown also
for controls (C). Coronary cross-sectional area (CSA) is expressed in percent of resting luminal area. Normal vessel size remained
unchanged after phentolamine administration and increased during exercise both before and after administration of phentolamine or
nitroglycerin. The CSA of the stenotic vessel segments also remained unchanged after phentolamine administration. However, in
phentolamine-treated patients with or without chronic beta-blockade, paradoxical stenosis vasoconstriction was prevented during exercise.
Coronary vasoconstriction was reversible after nitroglycerin administration.
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cardial coronary resistance during sympathetic nerve stim-
ulation is even less pronounced than that of total coronary
resistance (19,20). Conversely, the decrease in epicardial
coronary diameter during cardiac sympathetic nerve stimu-
lation is minimal in the presence of chronic beta-blockade
(21). Alpha1-, as well as alpha2-adrenoceptors, however,
appear to be involved in norepinephrine-induced vasocon-
striction of human epicardial coronary arteries (22). Never-
theless, previous experimental and clinical data are conflict-
ing, and there is ongoing discussion on the influence of
alpha-adrenergic stimulation on coronary vasomotor tone.
Orlick and co-workers (23) postulated the presence of
alpha-adrenergic constrictor tone, because normally inner-
vated patients had a higher resting coronary resistance and
a higher coronary arterio-venous oxygen difference than did
cardiac transplant recipients. This difference was, however,
abolished by a nonselective alpha-blockade with phentol-
amine (23). No evidence for an influence of alpha-
adrenoceptors on a resting coronary tone has been found by
others in similar patient populations (24,25). Our data
confirm the relatively minor contributions of alpha-
adrenergic influences on coronary vasomotion of normal
coronary arteries, as alpha-adrenergic blockade did not
significantly affect epicardial coronary artery dimensions and
had no influence on coronary vasomotor tone at rest as well
as during exercise in patients with or without alpha-
blockade.
Alpha-adrenergic vasomotion in stenotic coronary arter-
ies. Compared with the normal coronary arteries, signifi-
cant alpha-adrenergic constriction of the stenotic coronary
arteries can be induced by cardiac sympathetic nerve stim-
ulation, resulting in the precipitation of myocardial ischemia
with regional wall-motion abnormalities and net lactate
production (26). In an experimental model, post-stenotic
coronary vasoconstriction that was prevented by intravenous
phentolamine or selective alpha2-blockade with rauwolscine
in the absence as well as in the presence of acute beta-
blockade was observed (26).
Under clinical conditions, sympathetic nerve activation
may be induced by isometric as well as dynamic exercise,
which may be involved in the narrowing of stenotic coronary
arteries (4,5). This narrowing of the epicardial coronary
segments can be prevented by administration of intracoro-
nary nitroglycerin or the calcium-antagonist diltiazem,
probably owing to the direct vasodilating properties of these
two agents.
The precise mechanism responsible for exercise-induced
vasoconstriction of stenotic vessel segments is not clear.
Besides an activation of the alpha-adrenergic sympathetic
nervous system, endothelial dysfunction with a decreased
production and/or release of nitric oxide, increased platelet
activation with release of serotonin and thromboxane A2,
and a passive collapse of the normal vessel wall within the
stenotic lesion (Venturi phenomenon) have been considered
as potential mechanisms. In the present study, nonselective
alpha-adrenoceptor blockade with intracoronary phentol-
amine was able to prevent vasoconstriction of the stenotic
arteries during exercise. These findings suggest that alpha-
adrenergic activation plays an important role in exercise-
induced vasoconstriction of stenotic coronary segments
although it may not explain all mechanisms such as why the
stenotic vessel becomes reactive to circulating cat-
echolamines but not the normal vessel. Preexisting endo-
thelial dysfunction may render the stenotic vessel sensitive
to circulating catecholamines; in other words, the function-
ing endothelium releases NO, which overruns the vasocon-
strictor effects of the alpha-adrenergic system. Blockade of
these vasoconstrictor effects prevents, therefore, exercise-
induced vasoconstriction.
Previous data showed a decrease in exercise-induced
ST-segment depression and a reduction in angina pectoris
after intracoronary phentolamine administration (1). An
increase in exercise capacity after oral administration of
phentolamine (2) and indoramine (3), a selective alpha1-
adrenoceptor blocker has been reported in patients with
stable angina pectoris. Phentolamine was also able to prevent
coronary vasoconstriction during cold pressor testing (27) and
during isometric exercise (4), which are associated with stim-
ulation of the sympathetic nervous system (28).
In the absence of beta-blockade, alpha-blockade may
result in a decrease in coronary vascular resistance during
exercise due to presynaptic disinhibition of neuronal epi-
nephrine release, which results in an increase in oxygen
requirements. This may lead to metabolic vasodilation in
addition to the attenuation of alpha-adrenergic coronary
vasoconstriction. In the present study, chronic beta-
blockade was present in 5 of 16 phentolamine-treated
patients. Because coronary vasomotion in patients with and
without beta-blockade did not differ among each other, the
direct effect on arterial adrenoceptors appears to be more
important than metabolic vasodilation.
Although the various effects of alpha-adrenergic blockade
on post-stenotic coronary vasomotion have been previously
evaluated in dogs (26,29–31), the present study documents
for the first time a direct effect of alpha-adrenergic blockade
on coronary stenosis vasomotion during exercise in humans.
Table 3. Coronary Cross-Sectional Area: Absolute Values
Rest
(mm2)
Phentolamine
(mm2)
Exercise
(mm2)
NTG
(mm2)
Stenosis
Controls 1.9 6 1.0 1.7 6 1.4 2.2 6 1.2
a-Blocker 3.4 6 3.3 3.5 6 3.5 3.7 6 3.3 4.0 6 4.4
a 1 b-Blocker 4.0 6 2.8 4.3 6 2.9 4.4 6 2.9 4.6 6 2.8
Normal segment
Controls 6.1 6 3.8 6.8 6 4.6 7.3 6 4.5
a-Blocker 3.4 6 0.9 3.6 6 1.1 4.0 6 1.3 4.7 6 1.5
a 1 b-Blocker 8.0 6 4.3 8.6 6 4.7 9.3 6 3.4 10 6 3.9
a-Blocker indicates patients receiving phentolamine and a 1 b-Blocker patients on
chronic beta-blockade receiving phentolamine before supine bicycle exercise testing.
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The effects of alpha-adrenergic blockade were, however,
small in the normal vessel segment (Fig. 3) but large in the
stenotic segment. This may be explained by the fact that the
adrenergic vascular effects become much more prominent
when there is endothelial dysfunction with a reduced release
or production of NO. Beta-blocker administration may have
increased this response, which was, however, not the case in
the present study. One might have expected an even larger
effect owing to the blocking of the beta-mediated vasocon-
stricting effects, which did not become evident.
Clinical implications. Endothelial dysfunction is assumed
to occur in most stenotic coronary arteries, resulting in a
decreased flow to the post-stenotic regions, which may
precipitate myocardial ischemia during exercise. The func-
tional abnormalities of the endothelium and the enhanced
alpha-adrenergic sympathetic nervous system are probably
responsible for the occurrence of stenosis vasoconstriction
during exercise. Interestingly, a positive feedback mecha-
nism between myocardial ischemia and post-stenotic coro-
nary vasoconstriction has been described by Heusch and
co-workers in the canine model (31). Exercise-induced
vasoconstriction of the coronary arteries after balloon-
induced endothelial denudation has been previously shown
by Berdeaux and co-workers in dogs (32). Similarly, an
inhibitory role of the endothelium against alpha-adrenergic
nerve stimulation has been reported by Main et al. (33) in
isolated coronary artery rings from dogs with heart failure.
Endothelial cells of large canine and porcine coronary
arteries possess alpha2-adrenoceptors. Their activation by
norepinephrine causes release of an endothelium-derived
relaxant factor, which in turn attenuates norepinephrine-
induced vasoconstriction mediated by alpha1-adrenergic
coronary vasoconstriction. Conversely, loss of endothelial
function in atherosclerotic coronary arteries may predispose
to enhanced alpha-adrenergic coronary vasoconstriction
(34–36).
Alpha-blocking agents in general have rarely been used in
the treatment of coronary artery disease. Although these
drugs elicit an important vasodilatory effect, the clinically
limiting factors appear to be tachyphylaxis, an increase in
cardiac output and interference in the feedback inhibition of
norepinephrine release. Increased catecholamine release
may blunt the action of postsynaptic alpha-blockers.
Study limitations. Systemic effects of phentolamine in-
clude arterial hypotension with baroreflex-mediated sympa-
thetic activation and, thus, beta-adrenergic vasodilation
(13). However, no significant hemodynamic changes were
observed in the present study after intracoronary phentol-
amine injection, and, thus, it can be assumed that the
abolition of coronary stenosis vasoconstriction during exer-
cise is due to a direct effect on sympathetic alpha-
adrenoceptors.
The exact subtype of alpha-adrenoceptors involved in
paradoxical coronary stenosis vasoconstriction cannot be
derived from our study, as no selective alpha-blocker was
used. This issue was addressed in canine experiments as well
as in humans, but the results are controversial. Gwirtz and
colleagues (29) reported that post-stenotic vasoconstriction
during sympathetic nerve activation is abolished by selective
alpha1-antagonists, whereas Heusch and co-workers
(26,30,31) found that it was mediated by alpha2-
adrenoceptors. The existence of alpha2-adrenoceptors in
human coronary arteries has been documented by Indolfi
and co-workers (24). A reduction in exercise-induced ST-
segment depression and an increase in exercise capacity were
observed in patients with stable angina pectoris treated with
the selective alpha1-antagonist indoramine (3), whereas
exercise-induced ST-segment depression in a similar patient
group was more attenuated by the nonselective alpha-
antagonist phentolamine than the selective alpha1-
antagonist indoramine, suggesting an important role for
vascular alpha2-adrenoceptors in human coronary circula-
tion (37).
Conclusions. Nonselective alpha-adrenoceptor blockade
with intracoronary phentolamine is able to prevent exercise-
induced vasoconstriction of stenotic coronary arteries during
exercise. This observation suggests that alpha-adrenergic
sympathetic nerve activation plays an important role in
coronary stenosis vasomotion and may aggravate myocardial
ischemia during exercise in patients with stable angina
pectoris. These effects are probably unmasked as a conse-
quence of endothelial dysfunction with a decreased produc-
tion and reduced release of endogenous vasodilators from
the stenotic vessel segments leading to enhanced coronary
vasoconstriction during exercise.
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